Saidal and U.S. giant Abbott team up to scale high-tech pharma in Algeria

The Algerian pharmaceutical landscape is getting a high-tech boost as Saidal Group CEO Mourad Belkhalfa sat down with U.S. Chargé d’Affaires Marc A.

Shapiro and a delegation from American pharma giant Abbott at the Constantine 1 production site. The power meeting centered on their strategic partnership for the “Influvac” flu vaccine, a deal that signals growing confidence in Algeria’s industrial capacity. The U.S. team didn’t hold back on the praise, highlighting Saidal’s top-tier infrastructure and the technical muscle of its local workforce.

But this isn’t just about seasonal shots; Saidal is eyeing the cutting edge of biotech. Belkhalfa pitched the Americans on the group’s ambitious roadmap, including a groundbreaking cell therapy program that could redefine medical treatment in the region.

By doubling down on this alliance with Abbott, Saidal is positioning itself as a regional hub for innovation, aiming to swap traditional imports for locally manufactured, high-value health solutions. It’s a clear win-win that bridges American R&D with Algerian manufacturing scale.